SG11201803001WA - Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation - Google Patents

Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation

Info

Publication number
SG11201803001WA
SG11201803001WA SG11201803001WA SG11201803001WA SG11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA
Authority
SG
Singapore
Prior art keywords
antibody
affinity chromatography
pharmaceutical preparation
drug conjugate
cyclic peptide
Prior art date
Application number
SG11201803001WA
Other languages
English (en)
Inventor
Koichi Minami
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Priority claimed from PCT/JP2016/081353 external-priority patent/WO2017069269A1/fr
Publication of SG11201803001WA publication Critical patent/SG11201803001WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13Labelling of peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525Purification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
SG11201803001WA 2015-10-23 2016-10-21 Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation SG11201803001WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015209030 2015-10-23
PCT/JP2016/081353 WO2017069269A1 (fr) 2015-10-23 2016-10-21 Peptide cyclique, support de chromatographie d'affinité, anticorps marqué, conjugué anticorps-médicament et préparation pharmaceutique
JP2016206753A JP6554452B2 (ja) 2015-10-23 2016-10-21 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤

Publications (1)

Publication Number Publication Date
SG11201803001WA true SG11201803001WA (en) 2018-05-30

Family

ID=58803678

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803001WA SG11201803001WA (en) 2015-10-23 2016-10-21 Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation

Country Status (10)

Country Link
US (1) US10703778B2 (fr)
EP (1) EP3366693B1 (fr)
JP (1) JP6554452B2 (fr)
KR (1) KR102139057B1 (fr)
CN (1) CN108137651B (fr)
AU (1) AU2016340472B2 (fr)
BR (1) BR112018008117A2 (fr)
CA (1) CA3000979A1 (fr)
RU (1) RU2694050C1 (fr)
SG (1) SG11201803001WA (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201902818PA (en) * 2016-09-30 2019-05-30 Fujifilm Corp Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
WO2020075670A1 (fr) * 2018-10-10 2020-04-16 国立大学法人鹿児島大学 Peptide de liaison à l'igg comprenant un support en phase solide, et procédé de séparation d'igg
BR112021023540A2 (pt) * 2019-05-24 2022-03-22 Avitide LLC Agentes de afinidade
JP7230197B2 (ja) * 2019-06-11 2023-02-28 富士フイルム株式会社 環状ペプチド、細胞足場材、細胞分離材、及び、培地

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
EP1240337B1 (fr) 1999-12-24 2006-08-23 Genentech, Inc. Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
ES2292638T3 (es) * 2000-11-08 2008-03-16 Fresenius Medical Care Affina Gmbh Peptidos, su preparacion y su uso para la union a inmunoglobulinas.
CA2444680A1 (fr) 2001-04-18 2002-10-31 Dyax Corp. Molecules de liaison pour les polypeptides de zone fc
CA2456964A1 (fr) * 2001-08-08 2003-02-20 Merck & Co., Inc. Antagonistes d'hormone concentrant la melanine
KR20040087765A (ko) 2003-04-09 2004-10-15 주식회사 일산 관체 성형방법 및 그 장치
WO2012040259A2 (fr) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Compstatine modifiée ayant des propriétés de stabilité et de liaison améliorées
EP2749646B1 (fr) 2011-08-24 2018-03-21 Kagoshima University Peptide de liaison à l'immunoglobuline g et procédé de détection et d'épuration d'immunoglobuline g mettant en oeuvre un tel peptide
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure

Also Published As

Publication number Publication date
RU2694050C1 (ru) 2019-07-09
KR20180041243A (ko) 2018-04-23
JP6554452B2 (ja) 2019-07-31
EP3366693A4 (fr) 2018-12-05
CN108137651B (zh) 2022-02-22
AU2016340472A1 (en) 2018-05-10
BR112018008117A2 (pt) 2018-11-06
US20180230184A1 (en) 2018-08-16
JP2017095443A (ja) 2017-06-01
EP3366693B1 (fr) 2023-08-16
KR102139057B1 (ko) 2020-07-29
CA3000979A1 (fr) 2017-04-27
AU2016340472B2 (en) 2019-02-28
CN108137651A (zh) 2018-06-08
US10703778B2 (en) 2020-07-07
EP3366693A1 (fr) 2018-08-29

Similar Documents

Publication Publication Date Title
IL263600B1 (en) Antibodies against b7–h3 and drug-antibody conjugates
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
EP3284751A4 (fr) Anticorps anti-c-met, conjugué d'anticorps anti-c-met-médicament cytotoxique et leur utilisation pharmaceutique
SI3453707T1 (sl) Benzazepinski derivati, postopek priprave, farmacevtski sestavek in uporaba le-teh
HK1255566A1 (zh) 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用
IL291073A (en) Drug conjugates of anti-egfr antibodies
IL267834A (en) Conjugates of drug and antibody against CCR7
IL254098B (en) Compressed ring derivatives and method of preparation, intermediates, pharmaceutical preparations and their use
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
EP3250238A4 (fr) Conjugués anticorps-médicament
EP3491026A4 (fr) Anticorps humains, compositions pharmaceutiques et procédés
SG11202001647UA (en) Conjugate of vegf-grab protein and drug, and use thereof
EP3253212A4 (fr) Conjugués anticorps-médicament
SG11201803001WA (en) Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
EP3411382A4 (fr) Conjugué médicament-anticorps anti-egfr
EP3521300A4 (fr) Peptide cyclique, support de chromatographie d'affinité, anticorps marqué, conjugué anticorps-médicament, et préparation pharmaceutique
EP3308801A4 (fr) Conjugué anticorps-médicament, intermédiaire, procédé de préparation, compositions pharmaceutique et leurs utilisations
IL265645A (en) Monoclonal cmet binding agents, their drug conjugates and uses thereof
IL272920A (en) EGFR Antibody Drug Conjugates (ADC) and Their Uses
EP3476864A4 (fr) Anticorps dirigé contre etar, composition pharmaceutique et utilisation associées
EP3675908A4 (fr) Conjugués anticorps anti-egfr-médicament (adc) et utilisations associées
IL262929A (en) Preparations for treatment, methods for their preparation and their uses
EP3599250A4 (fr) Conjugué d'anticorps, composition pharmaceutique et application associées